Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS)

A Phase 2 Open-Label Study to Assess the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AKCEA-ANGPTL3-LRx (ISIS 703802) Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS)

This is a single center, open-label study to evaluate the efficacy of AKCEA-ANGPTL3-LRx for reduction of triglyceride (TG) levels in participants with FCS.

Key Inclusion Criteria:

• Genetically confirmed chylomicronemia syndrome.
• Fasting triglycerides greater than or equal to (>=) 750 milligrams per deciliter (mg/dL) [8.4 millimoles per liter (mmol/L)] at Screening.

Key Exclusion Criteria:

• Diabetes mellitus if newly diagnosed or if glycated hemoglobin (HbA1c) >= 9.0%.
• Active pancreatitis within 2 weeks of screening.
• Acute coronary syndrome within 6 months of screening.
• Major surgery within 3 months of screening.
• Treatment with Glybera therapy within 2 years of screening.
• Previous treatment with AKCEA-ANGPTL3-LRx.
• Have any other conditions in the opinion of the investigator which could interfere with the patient participating in or completing the study.